NCM
EW icon

Next Capital Management’s Edwards Lifesciences EW Stock Holding History

Next Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-129
Closed -$9K – 130
2019
Q3 		$9K Sell
129
-384
-75% -$27K 0.01% 232
2019
Q2 		$32K Buy
513
+384
+298% +$23.2K 0.02% 205
2019
Q1 		$8K Buy
+129
New +$7.36K 0.01% 230

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Next Capital Management's EW Position: Q4 2019 in Review

Next Capital Management sold out of Edwards Lifesciences (EW) in Q4 2019, closing a stake of 129 shares — an estimated $9K sold.

Next Capital Management first reported a position in EW in Q1 2019 and held it in 3 quarters. The position peaked at $32K in Q2 2019. 1,092 funds tracked by Wall St. Rank hold EW as of Q4 2019.

  • Next Capital Management reported no remaining Edwards Lifesciences position as of Q4 2019 after selling out during the quarter.
  • Next Capital Management sold 129 Edwards Lifesciences shares in Q4 2019, an estimated $9K.
  • Next Capital Management first reported a position in Edwards Lifesciences in Q1 2019 and held it in 3 quarters.
  • Next Capital Management's Edwards Lifesciences position peaked at $32K in Q2 2019.
  • 1,092 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2019.

Based on Next Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.